Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNA gp100 Antigen +/- IL-2 in Metastatic Melanoma
NCT00019448Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 1998
- Modality
- Prophylactic Vaccines, Gene Editing, Gene Silencing
- Countries
- 1
01
Overview
Phase 2, open-label trial of gp100 DNA vaccine in melanoma (5 cohorts), sponsored by National Cancer Institute. Primary endpoint: Clinical Response. Started Sep 1998; status: completed.
02
Drugs
gp100 DNA vaccine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00019448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00019448.